Background -There is growing evidence to suggest the importance of the lymphocyte in the pathogenesis of asthma, particularly in late phase reactions and ongoing bronchial hyperreactivity. Platelet activating factor (PAF) has also been identified as a potentially important mediator in asthma. Methods -The migration of human peripheral blood lymphocytes obtained from normal volunteers in response to PAF and the effect of PAF antagonists was studied in a well standardised in vitro assay using nitrocellulose micropore filters in a microchemotaxis chamber.
identified as a potentially important mediator in asthma. Methods -The migration of human peripheral blood lymphocytes obtained from normal volunteers in response to PAF and the effect of PAF antagonists was studied in a well standardised in vitro assay using nitrocellulose micropore filters in a microchemotaxis chamber. Results -PAF is a potent stimulus to in vitro human lymphocyte migration; at an optimal concentration of 1 nM it augmented lymphocyte chemokinesis to 310% (SE 33%) of control values. The response to PAF appears to be specific since lyso-PAF and other related membrane phospholipids had no effect. PAF-induced migration could be abrogated by specific PAF receptor antagonists such as WEB 2086 (100 nM), and was partially blocked by the cyclooxygenase inhibitor flurbiprofen at a concentration of 1 FIM.
Conclusions -PAF stimulates the in vitro migration of human lymphocytes through a specific PAF receptor. Part of the response may be due to the generation of cyclooxygenase products. PAF may play a part in the recruitment of lymphocytes to asthmatic airways. (Thorax 1995; 50:265-269) Keywords: asthma, lymphocytes, platelet activating factor (PAF).
lymphocytes are also involved in the pathogenesis of asthma, particularly in late phase reactions and ongoing bronchial hyperreactivity.7" A decrease in circulating CD4+
T lymphocytes is seen for up to 72 hours after allergen challenge in sensitised individuals,9 and circulating T cells in patients with acute asthma have been shown to bear markers of cell activation.'01' In studies employing bron Figure 1 shows the effect of various concentrations of PAF on the in vitro migration of lymphocytes purified by density centrifugation followed by nylon wool depletion; the response of mixed peripheral blood mononuclear cells before nylon wool depletion was qualitatively similar. As little as 100 pM PAF resulted in a significant increase in lymphocyte migration when compared with the response to buffer alone, and a peak response was seen with 1 nM PAF which augmented migration to levels 310 (33)% of control values.
The effect of various concentrations (10 pM-100 nM) ofcompounds related to PAF in the lymphocyte chemokinesis assay was studied. Lyso-PAF is both the immediate precursor and a catabolite of PAF, but this compound had no effect on in vitro lymphocyte migration. Related membrane phospholipids such as lysophosphatidylcholine, phosphatidylserine, and phosphatidic acid also had no effect. PAF has been reported to stimulate the release of histamine, serotonin, and substance P, but these compounds did not alter lymphocyte migration over a wide range of concentrations.
The chemokinetic response of lymphocytes to PAF could be blocked by various PAF re- (table) . This raises the possibility that the migratory response to PAF may be due in part to the release of eicosanoid products from either target lymphocytes themselves or the small number of contaminating monocytes present. Our results with the cyclooxygenase inhibitor flurbiprofen (fig 3) would suggest that PAF-induced lymphocyte chemokinesis may result from the release of a cyclooxygenase product such as HHT. In fact, HHT could partially restore PAF-induced lymphocyte migration that had been blocked by flurbiprofen. PAF is inextricably linked to arachidonic acid and its metabolites in all leucocyte membranes44 which makes direct and "indirect" effects of PAF difficult to separate. Finally, lymphocytes do not exist on their own in vivo, and the fact that nanomolar concentrations of PAF in vitro augment migration is still relevant to the inflammatory cascade seen in human disease states.
We have shown that human lymphocytes can be stimulated by PAF to migrate in an in vitro system. This suggests that the enhancement of leucocyte motility may be one of the most constant proinflammatory effects of PAF. Evidence is accumulating that PAF may play a part in many pathological conditions with a prominent inflammatory component. Although the recruitment and activation of lymphocytes is clearly dependent on multiple factors, we would suggest that PAF may be a contributor to this process. The role of PAF in leucocyte recruitment in asthma and other subacute pulmonary diseases characterised by lymphocyte and/or eosinophil infiltration should be evaluated.
